Cargando…

Radiation and Androgen Deprivation Therapy With or Without Docetaxel in the Management of Nonmetastatic Unfavorable-Risk Prostate Cancer: A Prospective Randomized Trial

Although docetaxel is not recommended when managing men with unfavorable-risk prostate cancer (PC) given negative or inconclusive results from previous randomized trials, unstudied benefits may exist. METHODS: Between September 21, 2005, and January 13, 2015, we randomly assigned 350 men 1:1 with T1...

Descripción completa

Detalles Bibliográficos
Autores principales:	D'Amico, Anthony V., Xie, Wanling, McMahon, Elizabeth, Loffredo, Marian, Medeiros, Shana, Joseph, David, Denham, Jim, Kumar, Parvesh, Bubley, Glenn, Sullivan, Molly, Hellwig, Richard, Carlos Vera, Juan, Freter, Rolf, Jeffrey Baker, W., Wong, Jeffrey Y., Renshaw, Andrew A., Kantoff, Philip W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2021
Materias:	ORIGINAL REPORTS
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8425842/ https://www.ncbi.nlm.nih.gov/pubmed/34197181 http://dx.doi.org/10.1200/JCO.21.00596

Ejemplares similares

Obesity and the Odds of Weight Gain following Androgen Deprivation Therapy for Prostate Cancer
por: Braunstein, Lior Z., et al.
Publicado: (2014)

Androgen Deprivation Therapy and Cardiovascular Risk in Chinese Patients with Nonmetastatic Carcinoma of Prostate
por: Huang, Gang, et al.
Publicado: (2014)

Intensification of Androgen Deprivation Therapy in High-Risk, Nonmetastatic Prostate Cancer: Lessons From STAMPEDE
por: Gong, Jun, et al.
Publicado: (2022)

Ten-year outcomes of high-dose intensity-modulated radiation therapy for nonmetastatic prostate cancer with unfavorable risk: early initiation of salvage therapy may replace long-term adjuvant androgen deprivation
por: Aizawa, Rihito, et al.
Publicado: (2019)

Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled Trial
por: James, Nicholas D, et al.
Publicado: (2022)

Natural History of Untreated Prostate Specific Antigen Radiorecurrent Prostate Cancer in Men with Favorable Prognostic Indicators
por: Martin, Neil E., et al.
Publicado: (2014)

Androgen deprivation therapy in nonmetastatic prostate cancer patients: Indications, treatment effects, and new predictive biomarkers
por: Fang, Dong, et al.
Publicado: (2019)

Bone health effects of androgen-deprivation therapy and androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer
por: Hussain, Arif, et al.
Publicado: (2020)

Decreased Expression of SETD2 Predicts Unfavorable Prognosis in Patients With Nonmetastatic Clear-Cell Renal Cell Carcinoma
por: Liu, Weisi, et al.
Publicado: (2015)

Prior-Cancer Diagnosis in Men with Nonmetastatic Prostate Cancer and the Risk of Prostate-Cancer-Specific and All-Cause Mortality
por: Mirabeau-Beale, Kristina, et al.
Publicado: (2014)

Three cases of nonmetastatic prostate cancer treated successfully with primary intermittent androgen deprivation therapy over 10 years
por: Shida, Yohei, et al.
Publicado: (2017)

Stereotactic body radiotherapy versus conventional/moderate fractionated radiation therapy with androgen deprivation therapy for unfavorable risk prostate cancer
por: Patel, Sagar A., et al.
Publicado: (2020)

Association between medical androgen deprivation therapy and long‐term cardiovascular disease and all‐cause mortality in nonmetastatic prostate cancer
por: Forster, Rachel B., et al.
Publicado: (2022)

Sequencing of Androgen-Deprivation Therapy of Short Duration With Radiotherapy for Nonmetastatic Prostate Cancer (SANDSTORM): A Pooled Analysis of 12 Randomized Trials
por: Ma, Ting Martin, et al.
Publicado: (2023)

Risk of Short-Term Prostate-Specific Antigen Recurrence and Failure in Patients With Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial
por: Sayan, Mutlay, et al.
Publicado: (2023)

National Cancer Database report of nonmetastatic esophageal small cell carcinoma
por: Verma, Vivek, et al.
Publicado: (2018)

A Large Nonmetastatic Anaplastic Thyroid Cancer with Complete Thyroidal Confinement
por: Xing, Jeffrey C., et al.
Publicado: (2011)

Exceptional pathologic complete response achieved with androgen deprivation and docetaxel therapy in Gleason 10 prostate cancer
por: Vaishampayan, Ulka, et al.
Publicado: (2019)

Survival Outcomes of Concurrent Treatment with Docetaxel and Androgen Deprivation Therapy in Metastatic Castration-Resistant Prostate Cancer
por: Jang, Ho Seong, et al.
Publicado: (2016)

Androgen Deprivation Therapy Reversibly Increases Endothelium‐Dependent Vasodilation in Men With Prostate Cancer
por: Nguyen, Paul L., et al.
Publicado: (2015)

Mortality Risk for Docetaxel-Treated, High-Grade Prostate Cancer With Low PSA Levels: A Meta-Analysis
por: Mahal, Brandon A., et al.
Publicado: (2023)

Efficacy of Androgen Deprivation Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Docetaxel-Based Chemotherapy
por: Min, Kyungchan, et al.
Publicado: (2020)

Transcriptional Profile Associated with Clinical Outcomes in Metastatic Hormone-Sensitive Prostate Cancer Treated with Androgen Deprivation and Docetaxel
por: Jiménez, Natalia, et al.
Publicado: (2022)

Nonmetastatic Castration-Resistant Prostate Cancer
por: Hong, Jun Hyuk, et al.
Publicado: (2014)

Androgen Deprivation Therapy Is Associated With Prolongation of QTc Interval in Men With Prostate Cancer
por: Gagliano-Jucá, Thiago, et al.
Publicado: (2018)

Cost-effectiveness analysis of abiraterone, docetaxel or placebo plus androgen deprivation therapy for hormone-sensitive advanced prostate cancer
por: Aguiar, Pedro Nazareth, et al.
Publicado: (2019)

Effectiveness of Adding Docetaxel to Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer in Korean Real-World Practice
por: Park, Kwonoh, et al.
Publicado: (2023)

Neighborhood and Individual Socioeconomic Disadvantage and Survival Among Patients With Nonmetastatic Common Cancers
por: Cheng, En, et al.
Publicado: (2021)

Darolutamide: a novel androgen-signaling agent in nonmetastatic castration-resistant prostate cancer
por: Aragon-Ching, Jeanny B
Publicado: (2019)

Current Role of Chemotherapy in Nonmetastatic Nasopharyngeal Cancer
por: Bhattacharyya, Tapesh, et al.
Publicado: (2018)

Use of docetaxel plus androgen deprivation therapy for metastatic hormone-sensitive prostate cancer in Korean patients: A retrospective study
por: Kwon, Whi-An, et al.
Publicado: (2019)

Efficacy and Safety of Androgen-Deprivation Therapy Combined with Docetaxel Plus Prednisone in High-Burden Metastatic Hormone-Sensitive Prostate Cancer
por: Hu, Linjun, et al.
Publicado: (2020)

ARASENS Trial: Should darolutamide now be added to androgen-deprivation therapy and docetaxel in patients with metastatic, hormone-sensitive prostate cancer?
por: Kumar, Naveen
Publicado: (2022)

Rupture of liver metastasis in high‐volume metastatic prostate cancer patient on androgen deprivation therapy combined with upfront docetaxel chemotherapy
por: Hata, Kenichi, et al.
Publicado: (2022)

Meditation as an intervention for cognitive disturbances following total sleep deprivation
por: Chatterjee, Abhirup, et al.
Publicado: (2012)

Addition of New Androgen Receptor Pathway Inhibitors to Docetaxel and Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review and Metanalysis
por: Fiorica, Francesco, et al.
Publicado: (2022)

Addition of androgen receptor-targeted agents to androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis
por: Maiorano, B.A., et al.
Publicado: (2022)

Diagnostic and therapeutic approaches for nonmetastatic breast cancer in Canada, and their associated costs
por: Will, B P, et al.
Publicado: (1999)

Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitors
por: Saad, Fred, et al.
Publicado: (2021)

Trimodal therapy with high-dose-rate brachytherapy and hypofractionated external beam radiation combined with long-term androgen deprivation for unfavorable-risk prostate cancer
por: Mori, Keiichiro, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mjr0susmsm2dted9ujglpnkjuk